AntriaBio

Financials

Investor Relations

Financials

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2017
Jun. 30, 2016
Current assets    
Cash $ 4,436,563 $ 4,062,013
Other current assets 413,037 430,094
Total current assets 4,849,600 4,492,107
Non-current assets    
Fixed assets, net 5,461,114 5,984,670
Intangibile assets, net 46,145 51,614
Deposit 375,000 375,000
Other non-current assets 63,233 0
Total non-current assets 5,945,492 6,411,284
Total Assets 10,795,092 10,903,391
Current liabilities:    
Accounts payable and accrued expenses 1,887,726 1,500,650
Convertible notes payable 10,000 60,000
Deferred lease liability, current portion 119,269 119,688
Lease payable 0 23,128
Interest payable 2,762 15,079
Warrant derivative liability 438 11,955
Total current liabilities 2,020,195 1,730,500
Non-current liabilities:    
Deferred lease liability, less current portion 314,655 400,038
Total non-current liabilities 314,655 400,038
Total Liabilities 2,334,850 2,130,538
Commitments and Contingencies (Note 11)
Stockholders' equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 45,452,450 and 35,110,916 shares issued and outstanding, March 31, 2017 and June 30, 2016 45,454 35,114
Additional paid-in capital 66,548,014 52,782,569
Accumulated deficit (58,133,226) (44,044,830)
Total stockholders' equity 8,460,242 8,772,853
Total Liabilities and Stockholders' Equity $ 10,795,092 $ 10,903,391
v3.7.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Research and development        
Compensation and benefits $ 1,859,699 $ 1,180,350 $ 5,073,057 $ 3,187,751
Consultants and outside costs 163,738 265,470 629,996 869,750
Material manufacturing costs 994,366 461,599 2,073,503 1,837,110
Facilities and other costs 421,292 402,770 1,223,847 907,721
Total research and development 3,439,095 2,310,189 9,000,403 6,802,332
General and administrative        
Compensation and benefits 1,187,379 907,626 3,339,332 3,025,476
Professional fees 278,031 106,791 564,047 344,964
Investor relations 103,657 88,138 259,192 202,458
General and administrative 382,535 302,731 940,650 706,380
Total general and administrative 1,951,602 1,405,286 5,103,221 4,279,278
Total operating expenses 5,390,697 3,715,475 14,103,624 11,081,610
Loss from operations (5,390,697) (3,715,475) (14,103,624) (11,081,610)
Other income (expense)        
Interest income 0 1 0 965
Interest expense 0 (1,143) (1,595) (4,135)
Rental income 5,306 0 5,306 0
Derivative gains 792 5,782 11,517 20,098
Total other income (expense) 6,098 4,640 15,228 16,928
Net loss (5,384,599) (3,710,835) (14,088,396) (11,064,682)
Warrant modification deemed dividend (3,366,070) 0 (3,366,070) 0
Cumulative Preferred Stock dividend 0 (61,279) 0 (61,279)
Net loss attributable to common stock $ (8,750,669) $ (3,772,114) $ (17,454,466) $ (11,125,961)
Net loss per common share - basic and diluted $ (0.21) $ (0.15) $ (0.44) $ (0.46)
Weighted average number of common shares outstanding - basic and diluted 42,216,495 24,338,219 39,446,695 24,338,219
v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (14,088,396) $ (11,064,682)
Amortization of intangible asset 5,469 5,469
Depreciation expense 829,258 476,941
Stock-based compensation expense 3,537,963 2,877,628
Derivative gains (11,517) (20,098)
Warrant expense 0 62,941
Changes in operating assets and liabilities:    
(Increase) decrease in other assets (233,676) (93,767)
Increase in accounts payable and accrued expenses 381,676 448,345
(Decrease) increase in interest payable (2,800) 1,500
Decrease in deferred lease liability (85,802) (30,868)
Net Cash Used In Operating Activities (9,667,825) (7,336,591)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (300,302) (1,774,413)
Return of security deposit 187,500 187,500
Decrease in restricted cash 0 450,167
Net Cash Used In Investing Activities (112,802) (1,136,746)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on lease payable (23,128) (70,033)
Proceeds from issuance of preferred stock 0 5,347,615
Proceeds from issuance of equity financings 10,861,499 0
Payment of placement agent compensation and issuance costs (683,194) (336,929)
Net Cash Provided by Financing Activities 10,155,177 4,940,653
Net increase (decrease) in cash 374,550 (3,532,684)
Cash - Beginning of Period 4,062,013 5,278,706
Cash - End of Period 4,436,563 1,746,022
Cash Paid During the Period for:    
Taxes 0 0
Interest 0 0
Non-Cash Transactions:    
Fixed assets acquired through accounts payable and accrued expenses 5,400 312,229
Warrant value recorded as issuance costs 516,550 250,163
Conversion of note payable into common stock 50,000 0
Conversion of interest payable into common stock 9,517 0
Fair value of warrant modifications recorded as a deemed dividend 3,366,070 0
Series A Preferred Stock dividend paid in stock $ 0 $ 61,279